Celyad Oncology SA announced updates from the Phase 1 alloSHRINK trial evaluating CYAD-101, the Company’s allogeneic NKG2D-receptor and T cell receptor (TCR) inhibitory molecule (TIM)-based, non-gene edited CAR T candidate administered concurrently with FOLFOX chemotherapy for the treatment of refractory metastatic colorectal cancer (mCRC), presented at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium (ASCO-GI), held virtually from January 15-17, 2021. Updated Clinical and Translational Data: Recent analysis of the dose-escalation segment of the alloSHRINK trial showed median overall survival (mOS) was 10.6 months; Tumor burden decrease was observed in eight of 15 patients, including six of nine patients at dose level 3 (1x109 cells per infusion); Of four patients treated at the highest dose level of 1x109 CYAD-101 cells per infusion available for analysis, three patients who achieved either a confirmed PR or SD also showed hyper-expanded TCR repertoire post-treatment through the emergence of new T cell clones in the peripheral blood T cell repertoire, while the patient with progressive disease displayed no evidence of new T cell clones; Cytokine modulation was also observed after the first and second infusions of CYAD-101 in the patient who achieved a confirmed PR from the highest dose level. Next steps: Preliminary data from the expansion cohort of the Phase 1 alloSHRINK trial are expected during the first half of 2021; Initiation of the Phase 1b KEYNOTE-B79 trial of CYAD-101 following FOLFIRI, with Merck’s KEYTRUDA in refractory mCRC patients with microsatellite stable (MSS) /mismatch-repair proficient (pMMR) disease is expected to be initiated during the first half of 2021.